Related Experiment Video
Updated: Jul 17, 2026
14:25
Synthesis of a Deuterated Standard for the Quantification of 2-Arachidonoylglycerol in Caenorhabditis elegans
Published on: September 21, 2019
The endocannabinoid system in neurodegeneration.
Natalia Battista1, Filomena Fezza, Alessandro Finazzi-Agrò
1Department of Biomedical Sciences, University of Teramo, Teramo, Italy.
The Italian Journal of Biochemistry
|February 6, 2007
Summary
Endocannabinoids, like anandamide and 2-AG, are bioactive lipids that activate cannabinoid receptors. Their pathway is crucial in neurodegenerative diseases, offering therapeutic targets.
Area of Science:
- Biochemistry
- Neuroscience
- Pharmacology
Background:
- Endocannabinoids are endogenous lipid signaling molecules.
- Anandamide (AEA) and 2-arachidonoylglycerol (2-AG) are key endocannabinoids acting on cannabinoid receptors.
- Their signaling is regulated by cellular uptake and enzymatic degradation.
Purpose of the Study:
- To introduce the endocannabinoid system.
- To review the role of endocannabinoids in neurodegenerative disorders.
- To discuss potential therapeutic strategies targeting the endocannabinoid system.
Main Methods:
- Literature review of endocannabinoid research.
- Discussion of endocannabinoid transport and metabolism.
- Analysis of the endocannabinoid system's involvement in disease.
Main Results:
- The endocannabinoid system comprises endocannabinoids and their associated proteins.
- Endocannabinoid pathways are implicated in Parkinson's, Huntington's, and multiple sclerosis.
- Pharmacological modulation of this system shows therapeutic potential.
Conclusions:
- The endocannabinoid system is a significant area of research for neurological conditions.
- Targeting endocannabinoid receptors or metabolism may lead to novel treatments.
- Further investigation is warranted for developing next-generation therapeutics.
Related Concept Videos
01:23Alzheimer Disease ll: Pathophysiology
Alzheimer disease involves structural changes in the brain that begin long before symptoms appear. The most distinctive features are extracellular neuritic plaques and intracellular neurofibrillary tangles.Neuritic plaques form in the cerebral cortex and around blood vessels. These plaques contain a dense core of beta-amyloid (Aβ)—a toxic protein fragment that clumps outside neurons. The core is surrounded by damaged neuronal extensions, as well as reactive astrocytes and microglia. Abnormal...
01:24CNS Stimulants: Cocaine, Amphetamines and Cannabinoids
CNS stimulants, such as cocaine, amphetamines, and cannabinoids, have varying structures and mechanisms of action that lead to different therapeutic effects and side effects. Cocaine, with its molecular formula C17H21NO4, is a tropane alkaloid and a tertiary amino compound. It has two chemical forms: the hydrochloride salt and the "freebase." The former is in powder form, while the latter involves removing the hydrochloride salt to create a form that can be smoked. Cocaine exerts its effects by...
01:21Chemotherapy-Induced Nausea and Vomiting: Cannabinoids
Tetrahydrocannabinol (THC) is a phytocannabinoid that primarily interacts with the CB1 receptor, a type of G protein-coupled receptor (GPCR) predominantly in and around the chemoreceptor trigger zone (CTZ) and emetic center. THC also blocks the serotonin receptor activity in the dorsal vagal complex (DVC) by inhibiting serotonin release. THC exerts its anti-emetic effects through these interactions, which are beneficial for patients undergoing chemotherapy.
Two synthetic agonists of THC,...
Two synthetic agonists of THC,...
01:37Neural Regulation
Digestion begins with a cephalic phase that prepares the digestive system to receive food. When our brain processes visual or olfactory information about food, it triggers impulses in the cranial nerves innervating the salivary glands and stomach to prepare for food.
01:22Dementia l: Introduction
Dementia is an acquired, progressive syndrome characterized by a decline in multiple cognitive domains severe enough to impair daily functioning and reduce independence. Although memory loss is a central feature, the diagnosis requires additional deficits involving language, executive function, visuospatial skills, judgment, calculation, or abstract reasoning. These cognitive impairments reflect underlying neurodegenerative or vascular processes that gradually disrupt neuronal networks...
01:26Alzheimer's Disease: Overview
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ and tau...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ and tau...